Department of Gastroenterology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Cancer Epidemiol. 2011 Apr;35(2):165-9. doi: 10.1016/j.canep.2010.08.006. Epub 2010 Sep 21.
Today, the causal relationship between inflammation and gastric cancer is more widely accepted. Genetic variations in inflammation-related genes especially cytokines and their receptors, were thought to partly determine the outcome of Helicobacter pylori (H. pylori) infection and progression of gastric lesions. Interleukin 23 receptor (IL23R), as a key cytokine receptor gene in the important inflammatory IL-17/IL-23 axis, may contribute to gastric cancer predisposition. Up till now, the associations of IL23R gene polymorphisms with subtypes of gastric cancer are largely unknown.
We investigated whether the association between IL23R +2199 rs10889677 and gastric cancer risk varies by clinical characteristics and the prognostic value of the polymorphism in a case-control study.
A population-based case-control study was conducted in Guangdong. 1010 gastric cancer patients and 800 healthy controls were enrolled. Polymorphism in IL23R was analyzed by PCR-RFLP.
Compared with AA, CC carriers of IL23R +2199 polymorphism were associated with protection against gastric cancer (OR=0.47, 95% CI=0.31-0.71). In stratified analyses, CC genotype was significantly associated with decreased risk of intestinal type (OR=0.44, 95% CI=0.27-0.70), but not with diffuse or mix type of gastric cancer. CC genotype was found to be associated with poorly differentiated (OR=0.43, 95% CI=0.26-0.70), but not with moderately or well differentiated gastric cancer. Multivariate analysis showed IL23R +2199A/C variant was not an independent prognostic factor for gastric cancer patients.
IL23R polymorphism influences certain subtypes of gastric cancer according to clinical and pathological features. Understanding the etiologic heterogeneity of gastric cancer may result in improvements in controlling this disorder.
我们通过病例对照研究来探究 IL23R+2199 rs10889677 与胃癌风险之间的关联是否因临床特征而有所不同，以及该多态性的预后价值。
在广东进行了一项基于人群的病例对照研究。纳入了 1010 名胃癌患者和 800 名健康对照者。采用 PCR-RFLP 法分析 IL23R 多态性。
与 AA 相比，IL23R+2199 多态性的 CC 携带者患胃癌的风险较低（OR=0.47，95%CI=0.31-0.71）。在分层分析中，CC 基因型与肠型胃癌的风险降低显著相关（OR=0.44，95%CI=0.27-0.70），但与弥漫型或混合型胃癌无关。CC 基因型与低分化（OR=0.43，95%CI=0.26-0.70）相关，而与中或高分化胃癌无关。多变量分析显示，IL23R+2199A/C 变异不是胃癌患者的独立预后因素。
IL23R 多态性根据临床和病理特征影响特定类型的胃癌。了解胃癌的病因异质性可能有助于控制这种疾病。
